• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Germany’s Federal Ministry of Education and Research (BMBF) grants additional funding to six PDPs fighting poverty-related and neglected tropical diseases

Home > Press releases

Germany’s Federal Ministry of Education and Research (BMBF) grants additional funding to six PDPs fighting poverty-related and neglected tropical diseases

Healthcare workers with patients in a hospital ward
Berlin / Geneva — 13 Jan 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • Deutsch
    • English

The German Federal Ministry of Education and Research (BMBF) through KfW has granted additional funding to six non-profit organizations that focus on research and development (R&D) of affordable and accessible vaccines, treatments, diagnostics, and prevention technologies for neglected populations.

The Drugs for Neglected Diseases initiative (DNDi), FIND, the global alliance for diagnostics, the International Partnership for Microbicides (IPM), Medicines for Malaria Venture (MMV), PATH, and TB Alliance will receive a total of EUR 15.1 million to ensure the continuity of R&D tools for HIV/AIDS, malaria, tuberculosis (TB), and neglected tropical diseases (NTDs).

This funding for 2021-2022 follows the German government’s most recent 2016-2020 funding period for product development partnerships (PDPs). BMBF through KfW has supported PDPs since 2011.

This new commitment is particularly important given the COVID-19 pandemic, which continues to have a negative impact on communities already hard-hit by these diseases. The COVID pandemic is also threatening progress toward achieving United Nations Sustainable Development Goal 3 – ‘Ensure healthy lives and promote well-being for all at all ages.’

Operating on a not-for-profit basis, PDPs prioritize access and affordability during the R&D process to ensure that global health innovations reach the patients who need them. International cooperation in R&D – one of the central tenets of the PDP model – is a key focus of the ‘Global Health Strategy of the German Federal Government’. German government support to date has enabled PDPs to collaborate across borders and across the public, private, civil society, academic, and philanthropic sectors to develop innovative solutions to pressing health problems.

Since 2010, twelve leading PDPs have developed and introduced 66 new health technologies, which have reached more than 2.4 billion people around the world, including women, children, and other populations often ignored by traditional models of R&D. This progress would not be possible without the support of BMBF and other public and philanthropic funders.

This additional funding underlines BMBF’s vital commitment to global health research and R&D models that ensure the availability of new medical tools and progress in neglected research areas. Germany’s recent coalition treaty states that the new government will ‘intensify the fight against poverty-related and neglected tropical diseases.’

Germany’s upcoming G7 presidency will be an opportunity to show commitments to international cooperation in global health R&D, including this renewed support for PDPs.

More details on the supported PDPs and projects:

  • DNDi: BMBF through KfW has been a key DNDi donor since 2012, supporting a wide range of R&D initiatives aimed at delivering affordable and accessible treatments for people affected by NTDs. For example, the Ministry co-financed the development of fexinidazole and acoziborole, two game-changing treatments for sleeping sickness – a deadly disease that affects people in very remote, hard-to-reach Central African communities. With this additional funding, DNDi will continue developing treatments for the most neglected tropical diseases while also conducting exploratory assessments to examine research gaps for dengue fever, snakebite, and schistosomiasis.
  • FIND: With support from the German government, FIND, the global alliance for diagnostics, and its partners have made progress in accelerating testing technologies that have significant impact at lower levels of the health system for TB, Buruli ulcer, and Lassa fever. The additional funding provided will allow FIND to continue this work until December 2022 and support late-stage development and evaluation for roll-out of these innovative testing technologies.
  • IPM: BMBF through KfW has been a longstanding supporter of IPM’s mission to expand women’s HIV prevention options. Previous funding was critical to IPM’s monthly dapivirine vaginal ring (DVR) becoming the first long-acting and woman-controlled HIV prevention product to receive a positive European Medicines Agency opinion, WHO recommendation and approvals in several countries in Africa. The additional funding will support: continued regulatory submissions in eastern and southern Africa, where the need for new prevention methods is urgent; preparations for the ring’s introduction where it is approved; and R&D for a follow-on DVR that could be used for three months at a time.
  • MMV: BMBF’s incremental funding to MMV continues to support key R&D activities under the three priority areas of discovery, translational medicine, and product development. Of particular note is the increased attention on ensuring the development of medicines suitable for children and women of childbearing potential – the groups most at risk of malaria.
  • PATH: Through KfW, BMBF has supported PATH’s work in low resource settings evaluating vaccines against malaria and cervical cancer over the past several years. Additional commitments from BMBF will augment their funding for a clinical trial of an affordable human papillomavirus (HPV) vaccine in Bangladesh and Ghana to address impacts related to the COVID-19 pandemic.
  • TB Alliance: With additional funding, TB Alliance continues to pursue necessary further breakthroughs in TB therapy – shorter regimens of safer and more effective drugs – to accelerate the reduction of the TB disease burden, and ultimately achieve its elimination. Specifically, TB Alliance will continue rolling out the breakthrough BPaL regimen, striving for updated global guidance and additional regulatory approvals for the regimen to be used in highly drug-resistant TB patients. Concurrently, TB Alliance is developing a universal regimen that is effective against all forms of TB, by researching safer oxazolidinones and diarylquinolines.

Media contact

DNDi
Frédéric Ojardias
Senior Press Officer
fojardias@dndi.org
+41 79 431 6216

FIND
Sarah-Jane Loveday
Director of Communications
+41 (0) 79 431 62 44
media@finddx.org

IPM
Holly Seltzer
Senior Director, Communications
+1 3016084277
HSeltzer@ipmglobal.org

MMV
Elizabeth Poll
Director, Communications
+41 79 907 5992
polle@mmv.org

PATH
Lindsay Bosslet
Director of Marketing, Communications and Creative
media@path.org

TB Alliance
Thomas Lynch
+1 917 648 0671
Thomas.Lynch@tballiance.org

Photo credit: Lameck Ododo/DNDi

Funding Sustainable Development

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo